

## Supporting Information

### **Dimethylmyricacene: an *in vitro* and *in silico* study of a semisynthetic non-camptothecin derivative compound, targeting human DNA topoisomerase 1B.**

Alessio Ottaviani<sup>a,d\*</sup>, Federico Iacovelli<sup>a</sup>, Joshua Welsch<sup>b</sup>, Blasco Morozzo della Rocca<sup>a</sup>, Alessandro Desideri<sup>a</sup>, Mattia Falconi<sup>a</sup>, Laurent Calcul<sup>b</sup>, Bill J. Baker<sup>b</sup> and Paola Fiorani<sup>a,c</sup>.

#### AUTHORS ADDRESSES

<sup>a</sup>Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.

<sup>b</sup>Department of Chemistry, University of South Florida, Tampa, FL, USA

<sup>c</sup>Institute of Translational Pharmacology, National Research Council, CNR, 00133 Rome, Italy.


<sup>d</sup> Department of Onco-hematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, 00146 Rome, Italy.

A.O. present address. Department of Onco-hematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.


\*Corresponding author email: [alessio.ottaviani@uniroma2.it](mailto:alessio.ottaviani@uniroma2.it)

#### TABLE OF CONTENTS:


Figure S1	S2
Figure S2	S3
Figure S3	S4
Figure S4	S5
Table S1	S6




**Figure S1.** Inhibition of catalytic activity of hTop1 by Myricanol and its derivatives. Relaxation assay in presence of 100  $\mu$ M of the myricanol **1**, dimethylmyricacene **2**, dimethylmyricanol **3** and myricanol triacetate **4**. Samples were incubated for 1 h at 37°C, resolved on an agarose gel, stained with EtBr and the bands were visualized by UV transilluminator. ACN, represent the positive control where supercoiled DNA is incubated with solvent and enzyme; C, is the negative control with supercoiled DNA only. SC supercoiled.



**Figure S2.** 3D structure of the hTop1-DNA in complex with the intercalated drug after 50 ns of MD simulation time. The hTop1 structure is represented as a blue cartoon, the DNA is shown as red ribbons, the drug as spheres. The analysis of this configuration suggests a partial rearrangement of the **2** within the binding site, allowing its interaction with the loops composing the “lips” of the hTop1, highlighted by the green color.



**Figure S3.**  $^1\text{H}$  NMR spectrum of dimethylmyricacene (600 MHz,  $\text{CDCl}_3$  on a Varian 600 MHz broadband instrument)



**Figure S4.** Ramachandran graph for 1T8I crystal structure: green crosses on the grey regions mean favourable torsion angles (502 residues, 97.3%), orange filled triangles on the border regions means allowed torsion angles (12 residues, 2.3%), while red filled circles mean outlier side chain torsion (2 residues, 0.4%).

**Table S1.** *In silico* ADMET properties for DM as predicted by ADMETlab2.0 server (in the following pages)

## 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	368.2	Contain hydrogen atoms. Optimal:100~600
Volume	397.4	Van der Waals volume
Density	0.927	Density = MW / Volume
nHA	4	Number of hydrogen bond acceptors. Optimal:0~12
nHD	0	Number of hydrogen bond donors. Optimal:0~7
nRot	4	Number of rotatable bonds. Optimal:0~11
nRing	3	Number of rings. Optimal:0~6
MaxRing	17	Number of atoms in the biggest ring. Optimal:0~18
nHet	4	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	21	Number of rigid bonds. Optimal:0~30
Flexibility	0.19	Flexibility = nRot / nRig
Stereo Centers	0	Optimal: ≤ 2
TPSA	36.92	Topological Polar Surface Area. Optimal:0~140
logS	-6.326	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	5.293	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	4.077	logP at physiological pH 7.4. Optimal: 1~3

## 2. Medicinal Chemistry

Property	Value	Decision	Comment
QED	0.694	●	<ul style="list-style-type: none"> <li>■ A measure of drug-likeness based on the concept of desirability;</li> <li>■ Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	4.183	●	<ul style="list-style-type: none"> <li>■ Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>■ SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.391	●	<ul style="list-style-type: none"> <li>■ The number of sp<sup>3</sup> hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥ 0.42 is considered a suitable value.</li> </ul>
MCE-18	39.312	●	<ul style="list-style-type: none"> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18 ≥ 45 is considered a suitable value.</li> </ul>

NPscore	1.046	-	<ul style="list-style-type: none"> <li>■ Natural product-likeness score.</li> <li>■ This score is typically in the range from -5 to 5. The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>
Lipinski Rule	Accepted	●	<ul style="list-style-type: none"> <li>■ <math>MW \leq 500</math>; <math>\log P \leq 5</math>; <math>Hacc \leq 10</math>; <math>Hdon \leq 5</math></li> <li>■ If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>
Pfizer Rule	Rejected	●	<ul style="list-style-type: none"> <li><math>\log P &gt; 3</math>; <math>TPSA &lt; 75</math></li> <li>Compounds with a high log P (&gt;3) and low TPSA (&lt;75) are likely to be toxic.</li> </ul>
GSK Rule	Rejected	●	<ul style="list-style-type: none"> <li>■ <math>MW \leq 400</math>; <math>\log P \leq 4</math></li> <li>■ Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>
Golden Triangle	Accepted	●	<ul style="list-style-type: none"> <li>■ <math>200 \leq MW \leq 500</math>; <math>-2 \leq \log D \leq 5</math></li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.
ALARM NMR	0 alerts	-	Thiol reactive compounds.
BMS	0 alerts	-	Undesirable, reactive compounds.
Chelator Rule	0 alerts	-	Chelating compounds.

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-4.786	●	Optimal: higher than -5.15 Log unit
MDCK Permeability	1e-05	●	<ul style="list-style-type: none"> <li>■ low permeability: <math>&lt; 2 \times 10^{-6}</math> cm/s</li> <li>■ medium permeability: <math>2-20 \times 10^{-6}</math> cm/s</li> <li>■ high passive permeability: <math>&gt; 20 \times 10^{-6}</math> cm/s</li> </ul>
Pgp-inhibitor	0.997	●	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.083	●	<ul style="list-style-type: none"> <li>■ Category 1: substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being Pgp-substrate</li> </ul>
HIA	0.003	●	<ul style="list-style-type: none"> <li>■ Human Intestinal Absorption</li> <li>■ Category 1: HIA+ (HIA &lt; 30%); Category 0: HIA- (HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	0.004	●	<ul style="list-style-type: none"> <li>■ 20% Bioavailability</li> <li>■ Category 1: F<sub>20%</sub><sup>+</sup> (bioavailability &lt; 20%); Category 0: F<sub>20%</sub><sup>-</sup> (bioavailability ≥ 20%); The output value is the probability of being F<sub>20%</sub><sup>+</sup></li> </ul>

$F_{30\%}$	0.08	●	<ul style="list-style-type: none"> <li>■ 30% Bioavailability</li> <li>■ Category 1: <math>F_{30\%}^+</math> (bioavailability &lt; 30%);</li> <li>Category 0: <math>F_{30\%}^-</math> (bioavailability <math>\geq</math> 30%); The output value is the probability of being <math>F_{30\%}^+</math></li> </ul>
------------	------	---	---

#### 4. Distribution

Property	Value	Decision	Comment
PPB	93.57%	●	<ul style="list-style-type: none"> <li>■ Plasma Protein Binding</li> <li>■ Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.588	●	<ul style="list-style-type: none"> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.028	●	<ul style="list-style-type: none"> <li>■ Blood-Brain Barrier Penetration</li> <li>■ Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	1.398%	●	<ul style="list-style-type: none"> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.809	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.951	<ul style="list-style-type: none"> <li>■ Category 1: Substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.927	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.829	<ul style="list-style-type: none"> <li>■ Category 1: Substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.79	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.934	<ul style="list-style-type: none"> <li>■ Category 1: Substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.481	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.947	<ul style="list-style-type: none"> <li>■ Category 1: Substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.771	<ul style="list-style-type: none"> <li>■ Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>■ The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.415	<ul style="list-style-type: none"> <li>■ Category 1: Substrate; Category 0: Non-substrate;</li> <li>■ The output value is the probability of being substrate.</li> </ul>

## 6. Excretion

Property	Value	Decision	Comment
CL	3.249	●	<ul style="list-style-type: none"> <li>■ Clearance</li> <li>■ High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.207	-	<ul style="list-style-type: none"> <li>■ Category 1: long half-life ; Category 0: short half-life;</li> <li>■ long half-life: &gt;3h; short half-life: &lt;3h</li> <li>■ The output value is the probability of having long half-life.</li> </ul>

## 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.725	●	<ul style="list-style-type: none"> <li>■ Category 1: active; Category 0: inactive;</li> <li>■ The output value is the probability of being active.</li> </ul>
H-HT	0.083	●	<ul style="list-style-type: none"> <li>■ Human Hepatotoxicity</li> <li>■ Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>■ The output value is the probability of being toxic.</li> </ul>
DILI	0.188	●	<ul style="list-style-type: none"> <li>■ Drug Induced Liver Injury.</li> <li>■ Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.022	●	<ul style="list-style-type: none"> <li>■ Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>■ The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.02	●	<ul style="list-style-type: none"> <li>■ Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>■ The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.864	●	<ul style="list-style-type: none"> <li>■ Maximum Recommended Daily Dose</li> <li>■ Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>■ The output value is the probability of being positive.</li> </ul>
Skin Sensitization	0.946	●	<ul style="list-style-type: none"> <li>■ Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>■ The output value is the probability of being sensitizer.</li> </ul>
Carcinogenicity	0.028	●	<ul style="list-style-type: none"> <li>■ Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>■ The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.003	●	<ul style="list-style-type: none"> <li>■ Category 1: corrosives ; Category 0: noncorrosives</li> <li>■ The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.065	●	<ul style="list-style-type: none"> <li>■ Category 1: irritants ; Category 0: nonirritants</li> <li>■ The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.017	●	<ul style="list-style-type: none"> <li>■ Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>■ The output value is the probability of being toxic.</li> </ul>
----------------------	-------	---	--

## 8. Environmental toxicity

Property	Value	Comment
Bioconcentration Factors	3.189	<ul style="list-style-type: none"> <li>■ Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>■ The unit is <math>-\log_{10}[(\text{mg/L})/(1000 \cdot \text{MW})]</math></li> </ul>
IGC <sub>50</sub>	5.099	<ul style="list-style-type: none"> <li>■ Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>■ The unit is <math>-\log_{10}[(\text{mg/L})/(1000 \cdot \text{MW})]</math></li> </ul>
LC <sub>50</sub> FM	7.049	<ul style="list-style-type: none"> <li>■ 96-hour fathead minnow 50 percent lethal concentration</li> <li>■ The unit is <math>-\log_{10}[(\text{mg/L})/(1000 \cdot \text{MW})]</math></li> </ul>
LC <sub>50</sub> DM	6.92	<ul style="list-style-type: none"> <li>■ 48-hour daphnia magna 50 percent lethal concentration</li> <li>■ The unit is <math>-\log_{10}[(\text{mg/L})/(1000 \cdot \text{MW})]</math></li> </ul>

## 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.113	●	<ul style="list-style-type: none"> <li>■ Androgen receptor</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.034	●	<ul style="list-style-type: none"> <li>■ Androgen receptor ligand-binding domain</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-AhR	0.811	●	<ul style="list-style-type: none"> <li>■ Aryl hydrocarbon receptor</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.758	●	<ul style="list-style-type: none"> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-ER	0.104	●	<ul style="list-style-type: none"> <li>■ Estrogen receptor</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.057	●	<ul style="list-style-type: none"> <li>■ Estrogen receptor ligand-binding domain</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
NR-PPAR-gamma	0.08	●	<ul style="list-style-type: none"> <li>■ Peroxisome proliferator-activated receptor gamma</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
SR-ARE	0.751	●	<ul style="list-style-type: none"> <li>■ Antioxidant response element</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.438	●	<ul style="list-style-type: none"> <li>■ ATPase family AAA domain-containing protein 5</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>

SR-HSE	0.214	●	<ul style="list-style-type: none"> <li>■ Heat shock factor response element</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
SR-MMP	0.699	●	<ul style="list-style-type: none"> <li>■ Mitochondrial membrane potential</li> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>
SR-p53	0.653	●	<ul style="list-style-type: none"> <li>■ Category 1: actives ; Category 0: inactives;</li> <li>■ The output value is the probability of being active.</li> </ul>

## 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 20 substructures</li> <li>■ acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 117 substructures</li> <li>■ carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 23 substructures</li> <li>■ carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	1 alerts	<ul style="list-style-type: none"> <li>■ 155 substructures</li> <li>■ skin irritation</li> </ul>
Aquatic Toxicity Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 99 substructures</li> <li>■ toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 19 substructures</li> <li>■ non-biodegradable</li> </ul>
SureChEMBL Rule	0 alerts	<ul style="list-style-type: none"> <li>■ 164 substructures</li> <li>■ MedChem unfriendly status</li> </ul>